Market Cap
$3.7B
TL
TLX
Telix Pharmaceuticals Ltd
$10.55 ▼ -1.59%
Prev close $10.72Market cap$3.7B
12-mo target$19.74 (+87.1%)
High Impact Filing (8/10)9 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on TLX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Inst. Holders
34 funds
Inst. Value
$25.9M
Inst. Activity
9 buys / 1 sells
Insider Activity
$1.0M buy / $0.00 sell
Insider Net $
$1.0M
SEC Reports
7
Press Releases
14
Price chart 30d -10.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 21, 2026 m_and_a
Sep 14, 2026 SEC Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceu
Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging dr
6-K — Impact 8/10
Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyrosine F 18), the first FDA-approved FET-PET imaging d
Impact 8/10
Sep 11, 2026 Event
PIXCLARA
Original Approval — Type 1 - New Molecular Entity — INJECTABLE
Sep 7, 2026 Insider
Sep 2, 2026 SEC Smith Darren Charlton bought 2,071 shares
Group Chief Financial Officer @ $9.66 ($20.0K)
Telix Pharmaceuticals completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix and Gozellix for pros
6-K — Impact 7/10
Telix completed enrollment (350 patients) in the Phase 3 BiPASS study evaluating Illuccix/Gozellix for pre-biopsy prosta
Impact 6/10
Telix reported a strong H1 2026 with revenue of $477.4M (+22% YoY), swinging to a net profit of $38.3M from a -$2.3M los
6-K — Impact 7/10
Analyst ratings
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 23, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 14, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 20, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Jul 7, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Jul 7, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jul 6, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Apr 13, 2026 | Wedbush | REITERATE | Outperform | 57% |
Price targets
Where 4 covering analysts think TLX trades over the next 12 months.
$19.74 +87.1% upside Strong Buy
Current$10.55 Low$15.41 Median$20.72 High$22.11 4 analysts
$15.41$22.11
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 6 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 6.1/10.Plus 14 press releases.
BULLISH6-K8/10
Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine F 18), the first FDA-approve
Sep 14, 2026
BULLISH6-K7/10
Telix Pharmaceuticals completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix a
Sep 2, 2026
BULLISH6-K7/10
Telix reported a strong H1 2026 with revenue of $477.4M (+22% YoY), swinging to a net profit of $38.
Aug 20, 2026
BULLISHPRESS-RELEASE7/10
Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, and a net profit of $38M vs a l
Aug 20, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 21, 2026
m_and_a
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) to
Sep 15, 2026
short_volume
Short Volume: TLX — 57.4% short (0.3M / 0.6M)
Short: 321,266 | Exempt: 15,128 | TRF Vol: 559,832 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
fda
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announc
Sep 11, 2026
FDA
PIXCLARA
Original Approval — Type 1 - New Molecular Entity — INJECTABLE
Sep 10, 2026
ftd
FTD: TLX — 42,551 shares ($0.5M) failed to deliver
Settlement: 20260910, Price: $12.34, FTD Value: $525,079.34, TELIX PHARMACEUTICALS LTD SPON
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.07 | $0.07–$0.07 | — | — | 0↑ 1↓ | $0.3B | 1 |
| Next Q | $0.07 | $0.07–$0.07 | — | — | 0↑ 1↓ | $0.3B | 1 |
| Current FY | $0.15 | $0.03–$0.39 | 597.0% | -3.9% | 3↑ 1↓ | $1.4B | 5 |
| Next FY | $-0.04 | $-0.04–$-0.03 | -125.6% | -118.7% | 0↑ 3↓ | $1.6B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.070 | — |
| 7d ago | $0.000 | +0.070 |
| 30d ago | $0.000 | +0.070 |
| 60d ago | $0.014 | +0.056 |
| 90d ago | $0.043 | +0.027 |
Institutional ownership
Which big funds own TLX (from quarterly 13F filings) and who is adding or trimming.
34 institutional holders with $25.9M total value (2,272,264 shares) as of 2026-Q2. Top holders: FMR, LAZARD, Private. Net buying activity: 9 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 561,206 | $6.5M | 25.0% | DOUBLED +357.0% |
| LAZARD ASSET MANAGEMENT LLC | 284,207 | $3.3M | 12.7% | DOUBLED +118.6% |
| Private Advisor Group, LLC | 197,250 | $2.3M | 8.8% | DOUBLED +276.3% |
| MARSHALL WACE, LLP | 189,188 | $2.2M | 8.4% | — |
| MORGAN STANLEY | 165,978 | $1.9M | 7.4% | ADD +42.5% |
| Integrated Wealth Concepts LLC | 164,397 | $1.9M | 7.3% | — |
| UBS Group AG | 134,698 | $1.6M | 6.0% | DOUBLED +317.0% |
| BLAIR WILLIAM & CO/IL | 122,985 | $1.4M | 5.5% | — |
| Quadrature Capital Ltd | 102,425 | $1.2M | 4.6% | — |
| JPMORGAN CHASE & CO | 77,538 | $876.2K | 3.4% | ADD +35.2% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 116,440 | 165,978 | +42.5% | $1.9M |
| UBS Group AG | DOUBLED | 32,300 | 134,698 | +317.0% | $1.6M |
| JPMORGAN CHASE & CO | ADD | 57,348 | 77,538 | +35.2% | $876.2K |
| Vanguard Personalized Indexing Management, LLC | ADD | 33,253 | 58,989 | +77.4% | $680.1K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 12,000 | 20,516 | +71.0% | $236.5K |
| Vident Advisory, LLC | TRIM | 16,653 | 11,955 | -28.2% | $137.8K |
| Arax Advisory Partners | DOUBLED | 125 | 2,152 | +1621.6% | $24.8K |
| OSAIC HOLDINGS, INC. | DOUBLED | 756 | 1,539 | +103.6% | $17.7K |
| BlackRock, Inc. | DOUBLED | 352 | 1,060 | +201.1% | $12.2K |
| Farther Finance Advisors, LLC | ADD | 9 | 14 | +55.6% | $161.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
2 insiders, 4 transactions. Net $1.0M — $1.0M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 7, 2026 | Smith Darren Charlton | Group Chief Financial Officer | BUY | 2,071 | $9.66 | $20.0K |
| Apr 29, 2026 | Behrenbruch Christian | MD & Group CEO | BUY | 33,435 | $14.87 | $497.2K |
| Apr 28, 2026 | Behrenbruch Christian | MD & Group CEO | BUY | 34,500 | $14.48 | $499.6K |
| Mar 29, 2026 | Smith Darren Charlton | Group Chief Financial Officer | EXERCISE | 1,111 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TLX.
Shares short
352,524
Settlement Sep 15, 2026
Change vs prior
+33.1%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.1%
Estimate — not % of float
All TLX filing & press-release reports (21)
- 6-K reportSep 14, 2026
- PRESS-RELEASE reportSep 14, 2026
- 6-K reportSep 2, 2026
- PRESS-RELEASE reportSep 1, 2026
- 6-K reportAug 20, 2026
- PRESS-RELEASE reportAug 20, 2026
- PRESS-RELEASE reportJul 30, 2026
- PRESS-RELEASE reportJul 21, 2026
- 6-K reportJul 21, 2026
- PRESS-RELEASE reportJul 21, 2026
- PRESS-RELEASE reportJul 20, 2026
- PRESS-RELEASE reportJul 15, 2026
- PRESS-RELEASE reportJul 2, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 13, 2026